



(51) International Patent Classification:

C07D 473/18 (2006.01) C07D 519/00 (2006.01)
A61K 31/522 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2017/083625

(22) International Filing Date:

19 December 2017 (19.12.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/436619 20 December 2016 (20.12.2016) US

(71) Applicants: **ASTRAZENECA AB** [SE/SE]; ".", SE-151 85 Södertälje (SE). **CANCER RESEARCH TECHNOLOGY LIMITED** [GB/GB]; Angel Building 407 St John Street, London EC1V 4AD (GB).

(72) Inventors: **FINLAY, Maurice, Raymond, Verschoyle**; AstraZeneca R&D Cambridge, Darwin Building Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0FZ (GB). **GOLDBERG, Frederick, Woolf**; AstraZeneca R&D Cambridge, Darwin Building Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0FZ (GB). **TING, Attila, Kuan, Tsuei**; AstraZeneca R&D Cambridge, Darwin Building Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0FZ (GB).

(74) Agent: **WALTON, Laura, Helen**; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER



(I)

(57) Abstract: The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where R¹ and R² have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.

